Diverse NACDS chain and supplier members developed health and wellness recommendations that leverage the total store for the total person.
The importance of the issue is underscored given rising rates of COVID-19 fueled by Omicron subvariants.
NACDS today welcomed the announcement by the U.S. Food and Drug Administration (FDA) that it revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), “to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.”
The decision offers hope for the ability of pharmacies to continue to meet patients’ needs in Washington State and across the nation.
NACDS’ sustained “Pharmacies. The face of neighborhood healthcare.” campaign tells the story of pharmacies’ effectiveness in serving the American public — in times of emergency and every day.
On Thursday, NACDS submitted a letter to the Biden Administration detailing five key recommendations to support a seamless transition of COVID-19 vaccinations from government-purchased product to commercially available supply — while maintaining patients’ critical access to care.
NACDS today announced that Jonathan Swan, national political reporter for Axios, will speak at the NACDS Political Involvement Reception during the 2022 NACDS Total Store Expo, which will be held August 27-29 in Boston, MA.
Registration is now open for the 2023 National Association of Chain Drug Stores (NACDS) Regional Chain Conference — “Focus on the Future” — to be held January 29-31 in Orlando, FL, during NACDS’ 90th Anniversary year.
Diverse NACDS-backed provisions would enhance patients’ access to OTC hearing aids and to biosimilar and generic medications, and would maintain flexibility in drug disposal options.
NACDS today announced two upcoming NACDS-led listening sessions to support the White House Conference on Hunger, Nutrition, and Health
